930 likes | 2.73k Views
Lipid Disorders and Their Management in Type 1 Diabetes Mellitus Robert H. Eckel, M.D. University of Colorado at Denver and Health Sciences Center Lipid Disorders and Their Management in Type 1 Diabetes Mellitus Lipid and lipoprotein metabolism in type 1 diabetes
E N D
Lipid Disorders and Their Management in Type 1 Diabetes MellitusRobert H. Eckel, M.D.University of Colorado at Denver and Health Sciences Center
Lipid Disorders and Their Management in Type 1 Diabetes Mellitus • Lipid and lipoprotein metabolism in type 1 diabetes • Relationship between lipids and lipoproteins and complications of type 1 diabetes • Management of lipid and lipoprotein disorders in type 1 diabetes
Lipid Disorders and Their Management in Type 1 Diabetes Mellitus • Lipid and lipoprotein metabolism in type 1 diabetes • Relationship between lipids and lipoproteins and complications of type 1 diabetes • Management of lipid and lipoprotein disorders in type 1 diabetes
Patients with Type 1 Diabetes in DCCT p Conventional Intensive Purnell, J.Q. et al Diabetes 44: 1220, 1995
Lipid Levels Adjusted for Age and Waist/Hip Ratio in Male Type 1 Diabetic and Control Subjects: CACTI * p < 0.001 for all Wadwa P et al, Diabetes Care, In Press
Lipid Levels Adjusted for Age and Waist/Hip Ratio in Female Type 1 and Control Subjects: CACTI * p < 0.01 for all Wadwa P et al, Diabetes Care, In Press
Lipid and Lipoprotein Abnormalities in Type 1 Diabetes • Hypertriglyceridemia (VLDL, IDL, remnants, apo B) • HDL cholesterol • Lipoprotein composition • TG • cholesterol/lecithin • Lp(a) (renal disease) • Glycation/oxidation
Cholesterol Metabolism in Type 1 Diabetes Miettinen TA et al, Diabetes Care 27:56, 2004
Fractional Escape Rates of LDL and Albumin in Type 1 Diabetes and Controls Konnerup K et al, Atherosclerosis 170:163, 2003
TG TG CE TG TG TG TG FC FC Extracellular Intracellular Apo A-1 Synthesis (liver, intestine) HDL2 Phospholipid (PL) Recycling CE rich HDL Free Cholesterol (FC) Synthesis FC SR-B1 mediated selective uptake of CE CE CE CE Lipid poor apo A1 FC FC Transfer of CE ABCA1 LDL FC + LCAT CE CE CE CE FC FC HDL3 CE CE FC CE Recyling from Lipoproteins FC Lipolysis Uptake by liver and other tissue Chol Ester (CE) Droplet FC Transfer of FC and PL Apo B VLDL
HDL in Type 1 Diabetes HDL cholesterol is typically normal or increased in type 1 diabetes!
* *p<0.001 * A-I/A-II Apolipoprotein Ratios in Men and Women with Type 1 Diabetes Men Women Eckel, RH et al. Diabetes 30:134-135, 1981
Factors Related to Lipid and Lipoprotein Levels in Diabetes • Glycemia • Obesity • Diet (Quantity and Composition) • Route of insulin administration • Genetic hyperlipidemia • Drugs • Alcohol and cigarette smoking • Nephropathy (Proteinuria and CRF)
Lipid Disorders and Their Management in Type 1 Diabetes Mellitus • Lipid and lipoprotein metabolism in type 1 diabetes • Relationship between lipids and lipoproteins and complications of type 1 diabetes • Management of lipid and lipoprotein disorders in type 1 diabetes
Renal Disease, Lipids and Diabetes Mellitus • Microalbuminuria • Often indicates or predicts lipoprotein abnormalities • Gross proteinuria • LDL, HDL, VLDL, Lp(a) • CRF • VLDL, HDL, Lp(a)
Difference Plot for Lipoproteins: Type 1 Diabetics with Micro- vs Normoalbuminuria Sibley, S.D. et al, Diabetes Care 22:1167, 1999
Difference Plot for Lipoproteins: Type 1 Diabetics with Macro- vs Normoalbuminuria Sibley, S.D. et al, Diabetes Care 22:1167, 1999
Incidence of CHD in Type 1 Diabetes: Effect of Nephropathy Tuomilehto, J. et al, Diabetologia 41:786, 1998
Incidence of Stroke in Type 1 Diabetes: Effect of Nephropathy Tuomilehto,J. et al, Diabetologia 41:786, 1998
Don’t forget about lipids and lipoproteins in type 1 diabetes and their to retinopathy and nephropathy!
What about lipid and lipoprotein metabolism and neuropathy in type 1 diabetes?
Male Sprague Dawley Rats STZ injection SQ (55 mg/Kg) Vehicle Sample nerve at different time points and measure LPL activity and mRNA and MNCV
Plasma Glucose 30 20 Glucose (mM) 10 0 STZ Vehicle Ferreira LDMC-B et al, Endo 143:1213, 2002
1 0 Motor Nerve Conduction Velocity Measurement *, P<0.001 0 * 8 0 6 0 MNCV (m/sec) 4 0 2 0 0 Control STZ n=4 n=5 Ferreira LDMC-B et al, Endo 143:1213, 2002
STZ 6 4 LPL 2 0 0 5 10 15 20 25 30 35 Days Sciatic Nerve LPL Activity * vs control, p<0.05 Vehicle (nmoles FFA/min/g) * * * * * Ferreira LDMC-B et al, Endo 143:1213, 2002
Plasma Glucose vs Sciatic LPL Activity r=0.623 p<0.001 6 LPL activity (nmoles FFA/min/g) 4 2 0 0 10 20 30 Glucose (mM) Ferreira LDMC-B et al, Endo 143:1213, 2002
Plasma Glucose 30 20 Glucose (mM) 10 0 Vehicle STZ + Ins STZ Ferreira LDMC-B et al, Endo 143:1213, 2002
LPL Activity After Insulin Treatment * vs STZ, p<0.05 10 * LPL (nmoles FFA/min/g) * 5 0 STZ STZ + Ins Vehicle Ferreira LDMC-B et al, Endo 143:1213, 2002
7 * 6 5 LPL activity (nmoles FFA/min/g) 4 # * # * 3 2 1 0 Veh STZ Insulin Phloridzin # p<0.05 vs Insulin * p<0.05 vs Vehicle Is It Glucotoxicity or Insulin Deficiency?
“With an excess of fat diabetes begins and from an excess of fat diabetics die . . .” EP Joslin, 1927
Cumulative Coronary Artery Disease Mortality in Type 1 Diabetes Krolewski, A.S. et al, Am J Card 59:750, 1987
Atherosclerosis and Type 1 Diabetes • mortality • 9x in men, 14x in women • Associated with • age • duration of disease • nephropathy • hypertension • lipid abnormalities
Atherosclerosis in Type 1 Diabetes • Is it simply glucose? • AGES • Oxidative stress • Endothelial dysfunction? • Precursor • Associated pathophysiology • Hypertension? • Nephropathy • Genetics? • Metabolic syndrome? • Inflammation and pro-thrombotic state included
Intensive Insulin Treatment and BMI: DCCT Purnell, J.Q. et al, JAMA 280:142, 1998
Lipid Levels at Follow-up By Quartile of Weight Gain in Intensively Treated Individuals: DCCT Purnell, J.Q. et al, JAMA 280:142, 1998
Lipoprotein Cholesterol Distribution after Intensive Insulinization : Effect of Change in BMI Purnell, J.Q. et al, JAMA 280:145, 1998